Regeneron Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
REGN Regeneron Pharmaceuticals Inc
PTON Peloton Interactive Inc
ETR Entergy Corp
ACMR ACM Research Inc
RGAGX American Funds The Growth Fund of America® Class R-6
ATRC AtriCure Inc
CTRA Coterra Energy Inc
CINF Cincinnati Financial Corp
ATOM Atomera Inc
IEAWW Infrastructure and Energy Alternatives 27 March 2023 *W EXP 03/27/2023
Go

Health Care : Biotechnology | Large Cap Blend
Company profile

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. It also provides Expresse service assurance and CloudCheck WiFi experience management solutions.

Postmarket

Last Trade
Delayed
$595.40
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$595.40
Day's Change
4.27 (0.72%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
597.00
Day's Low
586.17
Volume
(Light)
Volume:
382,439

10-day average volume:
785,365
382,439

Company Profile

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. It also provides Expresse service assurance and CloudCheck WiFi experience management solutions.

Valuation Ratios

Price/Earnings (TTM)
8.47x
Price/Sales (TTM)
3.98x
Price/Book (MRQ)
3.29x
Price/Cash Flow (TTM)
7.98x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

June 2022
Current Month
2.6M
Previous Month
2.1M
Percent of Float
2.45%
Days to Cover
3.2147 Days

Share Information

REGN is in a share class of common stock
Float
105.1M
Shares Outstanding
109.8M
Institutions Holding Shares
1,557
86.03%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • P. Roy VagelosChmn.
  • Leonard S. SchleiferPres.
  • George D. YancopoulosCo-Pres.
  • Robert E. LandryCFO
  • Joseph J. LaRosaExec.VP

Address

Insider Trading

During the most recent quarter, 108K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.